RaySearch Laboratories AB (publ) (RSLBF)
- Previous Close
0.00 - Open
12.40 - Bid 15.45 x 29200
- Ask 16.79 x 34100
- Day's Range
12.40 - 12.40 - 52 Week Range
6.45 - 15.62 - Volume
1,000 - Avg. Volume
38 - Market Cap (intraday)
549.74M - Beta (5Y Monthly) 1.34
- PE Ratio (TTM)
36.33 - EPS (TTM)
0.43 - Earnings Date Nov 8, 2024
- Forward Dividend & Yield 0.07 (0.42%)
- Ex-Dividend Date May 23, 2024
- 1y Target Est
--
RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer care in the Americas, Europe, Africa, the Asia-Pacific, and the Middle East. It develops and markets RayStation, a treatment planning system for radiation therapy; RayCare, an oncology information system that manages clinical activities; RayIntelligence, a cloud-based analytics system for monitoring and enhancement of cancer therapy; and RayCommand, a treatment control system that serves as link between the treatment machine and the treatment planning and oncology information systems. The company offers RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, and electron beam radiation therapy; and μ-RayStation, a software platform for planning and evaluation in small animal irradiation research. The company (publ) is headquartered in Stockholm, Sweden.
www.raysearchlabs.com411
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: RSLBF
View More
Performance Overview: RSLBF
Trailing total returns as of 9/20/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RSLBF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RSLBF
View MoreValuation Measures
Market Cap
549.74M
Enterprise Value
556.00M
Trailing P/E
36.20
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.85
Price/Book (mrq)
7.12
Enterprise Value/Revenue
5.02
Enterprise Value/EBITDA
27.91
Financial Highlights
Profitability and Income Statement
Profit Margin
13.40%
Return on Assets (ttm)
6.48%
Return on Equity (ttm)
20.76%
Revenue (ttm)
1.13B
Net Income Avi to Common (ttm)
151.22M
Diluted EPS (ttm)
0.43
Balance Sheet and Cash Flow
Total Cash (mrq)
435.2M
Total Debt/Equity (mrq)
64.94%
Levered Free Cash Flow (ttm)
268.15M
Company Insights: RSLBF
RSLBF does not have Company Insights